Bionime Corporation is a Taiwan-based company principally engaged in the manufacture and distribution of blood glucose monitoring products. The Company's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The Company distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	NT$54.00	-7.53%	210,932
11/09/26	NT$58.40	+0.17%	78,085
10/09/26	NT$58.30	+0.17%	81,249
09/09/26	NT$58.20	-1.02%	98,306
08/09/26	NT$58.80	-0.34%	82,691

End-of-day quote Taiwan S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Taiwan S.E. 14/09/2026			5-day change	1st Jan Change
54.00 ^TWD	-7.53%		-8.47%	-9.24%

08-12	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-13	Bionime Gets European Regulator's Certification for Glucose Monitoring System; Shares Jump 10%	MT

Market Cap	4.18B 131M 114M 107M 97.42M 183M 12.59B 184M 1.28B 494M 6.38B 493M 482M 20.3B	P/E 2024	-31x	P/E 2025	-22.2x
Enterprise Value	6.75B 212M 184M 174M 157M 295M 20.34B 298M 2.07B 799M 10.32B 797M 780M 32.81B	EV / Sales 2024	3.48x	EV / Sales 2025	3.58x
Free-Float	47.17%	Yield 2024 *	-	Yield 2025	-

08-12	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-13	Bionime Gets European Regulator's Certification for Glucose Monitoring System; Shares Jump 10%	MT
05-14	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-16	Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-13	Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/08/25	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
17/06/25	Bionime Corporation Approves Amendment to the Article of Incorporation	CI
12/05/25	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
10/04/25	Bionime Sees No Impact from US Reciprocal Tariffs	MT
12/11/24	Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
14/08/24	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
08/08/24	Bionime Corporation Announces Financial Officer Changes	CI
28/06/24	Bionime Corporation Approves Cash Dividends, Payable on August 23, 2024	CI

02/11/22	Bionime Announces the Introduction of Its Revolutionary iFree CGM for Diabetes Management Coming Soon	AQ
01/11/22	Bionime Corporation to Launch the Rightest iFree CGM, Proposed to Offer Precise and Accurate Blood Glucose Measurement and Monitoring	AQ
25/10/22	Bionime RIGHTEST iFree CGM System - An Innovative Approach to Keep Track of Every One Health	AQ
04/08/22	Bionime : Announcement of change the Globle Sales Division officer of the company.	PU
05/07/22	Bionime : Announcement of members of the first order audit committee of the Company.	PU

Bionime Corporation Stock

Stocks

4737

TW0004737002

Medical Equipment, Supplies & Distribution

Valuation: Bionime Corporation

Chart: Bionime Corporation

Latest news: Bionime Corporation

Press Releases: Bionime Corporation

Quotes and Performance

Price Extremes

Managers and Directors: Bionime Corporation

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 day	-7.53%
1 week	-8.47%
Current month	-6.25%
1 month	-5.10%
3 months	-1.64%
6 months	-10.60%
Current year	-9.24%

1 week	53.2	58.8
1 month	53.2	59.1
Current year	49.75	72.9
1 year	49.75	72.9
3 years	43.14	81.92
5 years	43.14	88.92
10 years	40.91	88.92

Manager	Title	Age	Since
Chun Mu Huang CEO	Chief Executive Officer	-	09/07/2010
Hui Chen Chen DFI	Director of Finance/CFO	-	06/11/2017
Zhi Long Yeh CTO	Chief Tech/Sci/R&D Officer	-	07/11/2018

Director	Title	Age	Since
Chun Mu Huang CHM	Chairman	-	14/04/2003
Tai Hsiung Chiang BRD	Director/Board Member	-	17/10/2007
Chien Hsing Lin BRD	Director/Board Member	-	28/06/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIONIME CORPORATION	-7.53%	-8.47%	-23.08%	-19.85%	131M
GUARDANT HEALTH, INC.	+2.20%	+9.04%	+220.37%	+494.41%	22.52B
BIOMÉRIEUX	+0.63%	-0.07%	-37.12%	-21.65%	9.72B
10X GENOMICS, INC.	+6.60%	+14.37%	+461.99%	+50.86%	9.13B
CARIS LIFE SCIENCES, INC.	+3.40%	+8.88%	-18.40%	-	7.36B
LANTHEUS HOLDINGS, INC.	+0.18%	+0.01%	+94.14%	+54.99%	6.55B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.75%	-4.69%	-28.99%	-22.57%	5.68B
DIASORIN S.P.A.	+0.08%	+0.46%	-5.54%	-19.71%	4.22B
ANDON HEALTH CO., LTD.	-3.58%	-14.94%	+50.90%	+61.40%	3.7B
AUTOBIO DIAGNOSTICS CO., LTD.	+1.89%	-2.40%	-22.85%	-30.45%	2.7B
Average	+0.48%	-0.66%	+69.14%	+60.83%	7.17B
Weighted average by Cap.	+1.95%	+2.02%	+128.82%	+181.50%

	2024	2025
Net sales	1.93B 60.81M 52.69M 49.73M 45.11M 84.63M 5.83B 85.24M 594M 229M 2.96B 228M 223M 9.4B	1.84B 57.82M 50.1M 47.28M 42.89M 80.46M 5.54B 81.04M 565M 218M 2.81B 217M 212M 8.94B
Net income	-127M -4M -3.47M -3.27M -2.97M -5.57M -383M -5.61M -39.07M -15.06M -195M -15.03M -14.69M -618M	-180M -5.67M -4.91M -4.64M -4.21M -7.89M -543M -7.95M -55.37M -21.33M -276M -21.29M -20.82M -876M
Net Debt	2.78B 87.55M 75.86M 71.59M 64.95M 122M 8.39B 123M 855M 329M 4.26B 329M 322M 13.53B	2.57B 80.94M 70.13M 66.18M 60.04M 113M 7.76B 113M 790M 305M 3.94B 304M 297M 12.51B